Keywords
compensation course of disease
peroral glucose lowering preparations
metformin
lactic acidosis
How to Cite
Abstract
In order to evaluate the rationality of the use of oral hypoglycemic agents retrospectively analyzed 106 medical histories of patients with diabetes mellitus type 2 aged 42 to 75 years. Among derivatives of sulfonylurea most commonly used glibenclamide (42.1%), and having the best pharmacological profile glimepiride – only at 28.0% of patients. Irrational use was detected in 20.8% of patients with severe cardiovascular disease, as well as in combination with medicines that change their glucose-lowering activity. Half of patients who treated with metformin, also identified the different types of irrational use. In particular, 24.5% of the patients it was combined with drugs potentiates the development of lactic acidosis. Improving the quality of diabetes treatment requires careful adjustment of pharmacotherapy, which justifies the need for participation in the process of clinical pharmacist.References
Аналіз діяльності ендокринологічної служби України у 2010 році / О.С. Ларін, В.І. Паньків, М.І. Селіваненко, О.О. Грачова // Міжнар. ендокринол. журнал. – 2011. – № 3 (35). – С. 10–18.
Diabetes and Cardiovascular Disease study group of the Société francophone du diabète (SFD), in collaboration with the Société française de cardiologie (SFC). Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome / B. Vergès, A. Avignon, F. Bonnet et al. // Diabetes Metab. – 2012. – № 2(38). – P. 113-127.
American Diabetes Association. Standards of Medical Care in Diabetes – 2012 // Diabetes Care. – 2012. – Vol. 35 (suppl.). – S. 30–32.
Nwaneri C. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis / C. Nwaneri, H. Cooper, D. Bowen-Jones // Br. J. Diabetes Vasc. Dis. – 2013. – № 4 (13). – P. 192–207.
Viljoen A. The tolerability and safety of DPP-4 inhibitors for the treatment of older people with type 2 diabetes mellitus: an observational study / A. Viljoen, C.L. Meek, R. Gadsby et al. // Br. J. Diabetes Vasc. Dis. – 2013. – № 4 (13). – P. 187–191.
Emergency hospitalizations for adverse drug events in older Americans / D.S. Budnitz, M.C. Lovegrove, N. Shehab, C.L. Richards // N. Engl. J. Med. – 2011. – № 21 (365). – P. 2002–2012.
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate / A.S. Levey, J. Coresh, T. Greene et al. // Ann. Intern. Med. – 2006. – № 4 (145). – P. 247–254.
Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study / K.H. Yoon, J.A. Shin, H.S. Kwon et al. // Diabetes Metab. J. – 2011. – № 1 (35). – P. 26–33.
Forbes J.M. Mechanisms of diabetic complications / J.M. Forbes, M.E. Cooper // Physiol. Rev. – 2013. – № 1 (93). – P. 137–188.
Asche C. A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes / C. Asche, J. LaFleur, Ch. Conner // Clin. Ther. – 2011. – № 1 (33). – P. 74–109.
Bailey C.J. Patient adherence to medication requirements for therapy of type 2 diabetes / C.J. Bailey, M. Kodack // Int. J. Clin. Pract. – 2011. – № 3 (65). – P. 314–322.
Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the compliance and biochemical control of type 2 diabetes) / P. Kardas // Diabetes Obes Metab. – 2005. – № 6 (7). – P. 722–728.
Lebovitz H.E. Type 2 diabetes: the evolution of a disease / H.E. Lebovitz // Br. J. Diabetes Vasc. Dis. – 2012. – № 6 (12). – P. 290–298.
Incidence and correlates of hypoglycemia in type 2 diabetes. The hypos-1 study / C.B. Giorda, A. Ozzello, S. Gentile et al. // J. Diabetes Metab. – 2014. – № 3 (5). – P. 344–352.
Metformin-associated lactic acidosis: predisposing factors and outcome / M.J. Kim, J.Y. Han, J.Y. Shin et al. // Endocrinol. Metab. (Seoul). – 2015. – № 1 (30). – P. 78–83.
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34000 patients / D.T. Eurich, D.L. Weir, S.R. Majumdar et al. // Circ Heart Fail. – 2013. – № 3 (6). – P. 395–402.
Variations in metformin prescribing for type 2 diabetes / T. Goldberg, M.E. Kroehl, K.H. Suddarth, K.E. Trinkley // J. Am. Board Fam. Med. – 2015. – № 6 (28). – P. 777–784.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus / S.R. Salpeter, E. Greyber, G.A. Pasternak, E.E. Salpeter // Cochrane Database Syst Rev. – 2010. – № 4 (14): CD002967
Paneni F. Metformin and left ventricular remodeling after acute myocardial infarction: molecular mechanisms and clinical implications / F. Paneni, S. Costantino, F. Cosentino // G. Ital. Cardiol. (Rome). – 2015. – № 4 (16). – P. 225–231.
Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial / C.P. Lexis, I.C. van der Horst, E. Lipsic et al. // JAMA. – 2014. – № 15 (311). – P. 1526–1535.
Clifford J. Bailey Diabetes therapies in renal impairment / J. Clifford // Br. J. Diabetes Vasc. Dis. – 2012. – № 4 (12). – P. 167–171.
Zammitt N.N. Hypoglycemia in type 2 diabetes. Pathophysiology, frequency, and effects of different treatment modalities / N.N. Zammitt, B.M. Frier // Diabetes Care. – 2005. – № 12 (28). – P. 2948–2961.
Толкачева В.В. Современные антигипергликемические препараты: механизмы действия и клинические эффекты / В.В. Толкачева, Т.М. Кичигина, Ж.Д. Кобалава // Клин. фармакология и терапия. – 2009. – № 2 (18). – С. 75–82.